Results 191 to 200 of about 986,336 (320)

Inferior Vena Cava Thrombosis in a Patient with Factor V Leiden Syndrome Presenting with Scrotal Pain. [PDF]

Case Rep Med, 2023
Elhag H, Al-Tairy F, Dahdaha MS, Shaeshaa A, Yigit Y.   +4 more
europepmc   +1 more source

Factor V Leiden Measurement [PDF]

, 2020
openaire   +1 more source

A multilevel perspective on MSH6‐associated Lynch syndrome: Integrating molecular, biological, and clinical insights

International Journal of Cancer, EarlyView.
Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia, Anne‐Sophie van der Werf‐'t Lam, Madalina Cabuta, Maartje Nielsen, Noah C. Helderman   +4 more
wiley   +1 more source

Recurrent arterial and venous thrombosis in a 39-year-old male with Factor V Leiden syndrome and aneurysmal disease: a case report and review of the literature. [PDF]

Thromb J
Mohammed A, Abdallah HO, Kharouf A, Hamed A.   +3 more
europepmc   +1 more source

Renal Vein Thrombosis Associated with Nephrotic Syndrome and Factor V Leiden. [PDF]

Indian J Nephrol, 2023
Torun C, Vural Keskinler M, Mesci B.
europepmc   +1 more source

Factor V leiden and ischemic stroke risk: the Genetics of Early Onset Stroke (GEOS) study.

Journal of Stroke & Cerebrovascular Diseases, 2013
A. Hamedani, J. Cole, Yuching Cheng, M. Sparks, J. O’Connell, O. Stine, M. Wozniak, B. Stern, B. Mitchell, S. Kittner   +9 more
semanticscholar   +1 more source

The Predictive Value of the Tumor‐Stroma Ratio for Neoadjuvant Endocrine Therapy in Hormone Receptor‐Positive Breast Cancer

International Journal of Cancer, EarlyView.
Neoadjuvant endocrine therapy (NET) can help prevent metastases and improve survival in patients with hormone receptor‐positive (HR+) breast cancer. Identifying which HR+ patients will benefit from NET, however, remains challenging. Here, in a patient cohort in the Netherlands, the authors evaluated tumor‐stroma ratio (TSR) and magnetic resonance ...
Layla Andour, Sophie C. Hagenaars, Anne Florine de Groot, Elly M. M. Krol‐Warmerdam, Judith R. Kroep, Hans Marten Hazelbag, Gerrit‐Jan Liefers, Marieke E. Straver, Wilma E. Mesker   +8 more
wiley   +1 more source

Ophthalmic Vein Thrombosis Associated with Factor V Leiden and MTHFR Mutations. [PDF]

Diagnostics (Basel), 2023
Teodoru CA, Munteanu M, Mercea N, Moatar A, Stanca H, Popescu FG, Dura H, Hașegan A, Giurgiu DI, Cerghedean-Florea ME.   +9 more
europepmc   +1 more source

Factor V Leiden: an overview.

Clinical laboratory science : journal of the American Society for Medical Technology, 2007
This paper provides an update and an overview of factor V Leiden, an inherited condition, which predisposes affected individuals to thrombosis. Factor V Leiden occurs due to a single point mutation on chromosome one. Tests for factor V Leiden include screening for activated protein C (APC) resistance, and if positive, testing for the Factor V Leiden ...
openaire   +1 more source

Transcriptome‐Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant Treatment

International Journal of Cancer, EarlyView.
Outcomes after resection of pancreatic ductal adenocarcinoma remain highly variable, and existing prognostic models lack sufficient accuracy. Here, the authors aimed to improve survival prediction by integrating transcriptome‐based subtyping into a validated clinical model and applying it to a multicenter real‐world cohort of fresh‐frozen resection ...
Marjolein F. Lansbergen, Vincent R. Lanting, Paul Manoukian, Marc G. Besselink, Geert Kazemier, Ignace H. J. T. de Hingh, Mike S. L. Liem, Casper H. J. van Eijck, Erwin van der Harst, Vincent E. de Meijer, Ronald M. van Dam, Martijn W. J. Stommel, Jan Koster, Michael W. T. Tanck, Arantza Fariña Sarasqueta, Joanne Verheij, Frederike Dijk, Johanna W. Wilmink, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven, for the Dutch Pancreatic Cancer Group   +20 more
wiley   +1 more source